Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GPNMB-directed CAR T cell therapy against MiT/TFE-family fusion-driven solid tumors.

Nature cancer·2026
Same author

Critical Appraisal: Prognostic versus Predictive Surrogate Markers in Oncology.

Journal of the National Cancer Institute·2026
Same author

Etiologies and Outcomes of Acute Respiratory Failure in Patients Treated with Immune Checkpoint Inhibitors.

Research square·2026
Same author

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

Cancer research communications·2026
Same author

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

JAMA network open·2026
Same author

Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium.

Clinical genitourinary cancer·2026

Related Experiment Video

Updated: Aug 10, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung

Vishal Navani1, Daniel E Meyers2, Yibing Ruan3

  • 1Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Clinical Lung Cancer
|February 11, 2023
PubMed
Summary

A new prognostic model, the Lung Immune Therapy Evaluation (LITE) risk score, identifies key factors for overall survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors.

Keywords:
ImmunotherapyLung cancerNSCLCPrognostic riskReal world data

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

568

Related Experiment Videos

Last Updated: Aug 10, 2025

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

568

Area of Science:

  • Oncology
  • Immunotherapy
  • Clinical Prognostics

Background:

  • Immune checkpoint inhibitors (ICI) have transformed non-small cell lung cancer (NSCLC) treatment.
  • Identifying prognostic factors for overall survival (OS) in NSCLC patients receiving ICI monotherapy is crucial.

Purpose of the Study:

  • To identify baseline characteristics that predict OS in NSCLC patients treated with ICI monotherapy.
  • To develop and validate a prognostic model, the Lung Immune Therapy Evaluation (LITE) risk score.

Main Methods:

  • A multi-center observational cohort study involving advanced NSCLC patients treated with ICI monotherapy.
  • Utilized penalized Cox regression for variable selection among 20 candidate prognostic factors.
  • Employed multiple imputation to handle missing data.

Main Results:

  • The LITE risk model incorporates ECOG performance status, lactate dehydrogenase levels, and neutrophil-to-lymphocyte ratio.
  • Patients were stratified into favorable, intermediate, and poor risk groups with distinct median OS (28.3, 9.1, and 2.1 months, respectively).
  • The model demonstrated good discriminative ability in both training (c-statistic 0.702) and external validation cohorts (c-statistic 0.664).

Conclusions:

  • A straightforward prognostic model using readily available clinical data can effectively predict survival outcomes in advanced NSCLC patients.
  • The LITE risk score provides valuable prognostic information for patients undergoing ICI monotherapy.